EP1816461B1 - Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse - Google Patents

Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse Download PDF

Info

Publication number
EP1816461B1
EP1816461B1 EP07008752.3A EP07008752A EP1816461B1 EP 1816461 B1 EP1816461 B1 EP 1816461B1 EP 07008752 A EP07008752 A EP 07008752A EP 1816461 B1 EP1816461 B1 EP 1816461B1
Authority
EP
European Patent Office
Prior art keywords
cells
tube
fixative
anticoagulant
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP07008752.3A
Other languages
English (en)
French (fr)
Other versions
EP1816461A1 (de
Inventor
Wayne L. Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Streck Inc
Original Assignee
Streck Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Streck Laboratories Inc filed Critical Streck Laboratories Inc
Priority claimed from EP20030256535 external-priority patent/EP1413874A1/de
Publication of EP1816461A1 publication Critical patent/EP1816461A1/de
Application granted granted Critical
Publication of EP1816461B1 publication Critical patent/EP1816461B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B01L3/5082—Test tubes per se
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L1/00—Enclosures; Chambers
    • B01L1/52—Transportable laboratories; Field kits

Definitions

  • the present invention relates to a method of preparing and the use for stabilising a sample of whole blood, epithelial or spinal fluid cells.
  • biological tissues i.e., cells and cellular components
  • the collected and preserved cells are often utilized-in a wide variety of applications, including but not limited to instructional aids and the diagnosis-and treatment of diseases.
  • such cells are often utilized in histological, cytological, immunological, and proteinaceous studies and the like.
  • Flow cytometry and flow cytometers are generally described in Keran's text, Flow cytometry in Clinical Diagnosis (1989 ).
  • Flow cytometers operate in principle by multiparameter analysis of heterogeneous cell populations (or cellular components) on a cell-by-cell basis.
  • Flow cytometry allows biological and physical properties of cells and cellular components to be determined.
  • cells in suspension are forced single file, via hydrodynamic focusing, through the path of a laser beam. Interaction of the cells with the laser beam scatters some of the light and causes excitation and emission from fluorescent molecules present on the surface or interior of the cell.
  • a series of lenses collect the scattered or emitted light and pass it to a photomultiplier. Each photomultiplier measures a separate parameter.
  • Parameters measured include: forward light scatter, which measures relative particle size; side light scatter, which measures relative granularity or other internal structure; and fluorescence emission.
  • the optical signals are converted by a computer to a data display for analysis and interpretation.
  • Cells collected and preserved using conventional methods and instruments generally require further dilution and/or treatment before they can be analyzed by flow cytometry.
  • tissue preservation The primary objective of tissue preservation is to provide as much structural detail of cells and components thereof as possible. To do this, it is necessary to maintain the cells in their original unaltered morphology so that maximum cellular detail may be observed. With the clinical application of immunostaining, there is also the requirement that antigens are not altered by the method of preservation. Thus, it is desirable in the art to obtain a method and a collection device that maintain the cells in their original unaltered morphology and preserve their antigenic sites.
  • the usual formulations for preservation of cells contain one or more agents, which react vigorously with the proteins of the cells to denature and insolubilize the components of the cell.
  • Typical of this type of agent is picric acid, mercuric ions, formaldehyde and glutaraldehyde.
  • some less toxic compounds can also be utilized which denature and stabilize the proteins such as acetic and formic acid.
  • the toxicity associated with such compounds renders their use less than satisfactory. For example, a 37% solution of formaldehyde, the most common of these fixatives, is a noxious gas which is also toxic, flammable, and carcinogenic.
  • fixative is selected from the group consisting of imidazolidinyl urea, diazolidinyl urea, and mixtures thereof.
  • the present application addresses many of the challenges encountered when using conventional methods and instruments to collect and preserve cells by providing a method and a collection device that are capable of maintaining the cells in their original unaltered morphology; preserving the cell antigenic sites; and allowing the cells to be transported at ambient temperature, to be handled in a low toxicity and non-flammable environment, and to be directly analyzed by flow cytometry without further dilution and/or treatment.
  • the claimed subject matter more specifically relates to a method and a device that allow cells (e.g., whole blood, epithelial cells, spinal fluid, and the like.) to be collected and preserved for analysis and addresses many of the challenges encountered when using conventional methods and instruments.
  • the claimed subject matter describes a method and a collection device that (1) use a less toxic and non-flammable reagent for fixing and stabilizing cells; (2) allow the cells to stay in their original unaltered morphology; (3) allow the cell antigenic sites to be preserved for a useful period of time; (4) allow the cells to be transported at ambient temperature; and/or (5) allow the cells to be directly analyzed by flow cytometry without further dilution and/or treatment.
  • the present application includes a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant agent and a fixative agent selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5-dimethylhydantoin, dimethylol urea, 2-bromo-2-nitropropane-1,3-diol, oxazolidines, sodium hydroxymethyl glycinate, 5-hydroxymethoxymethyl-1-laza-3, 7-dioxabicyclo[3.3.0]octane, 5-hydroxymethyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, 5-hydroxypoly[methyleneoxy]methyl-1-laza-3,7-dio
  • the claimed subject matter may optionally include polyacrylic acid or a suitable acid having a pH ranging from about one to about seven inside the tube.
  • the compounds of the device must be in a sufficient amount to preserve the collected cells' original morphology and antigenic sites without significant dilution of the cells (i.e., in a volume that is not clinically significant), and thereby allowing the cells, stored with the compounds, to be directly analyzed by a flow cytometer.
  • the present application also includes a method comprised of (1) providing a tube with an open end and a closed end, (2) preloading the tube with compounds including: an anticoagulant agent, a fixative agent selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5-dimethylhydantoin, dimethylol urea, 2-bromo-2-nitropropane-1,3-diol, oxazolidines, sodium hydroxymethyl glycinate, 5-hydroxymethoxymethyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, 5-hydroxymethyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, 5-hydroxypoly[methyleneoxy]methyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, and quaternary adamantine, and optionally
  • the method and device of the present application may also optionally include other art-disclosed components conventionally used in cell collection and analysis such as gauze, glove, tourniquet, lancet, needle, test strip (e.g., immunoassay), alcohol swab, tube holder, additional cell collection tubes (with or without conventional cell analysis additives inside these tubes), adhesive strip, syringe, glass or plastic strip, packaging means to store the desired components and the device, and packaging means to transport at least the collected and preserved cells stored in the device.
  • the method of the claimed subject matter may also optionally include additional art disclosed methods and instruments used for cell analysis such as a flow cytometer, a hematology analyzer, and other hematology instruments, etc.
  • FIG. 1 shows a cross-sectional illustration of a device 100 that incorporates a preferred embodiment of this claimed subject matter and can be used to collect and preserve biological tissues such as cells and cellular components for analysis.
  • the device 100 is particularly useful in the collection of whole blood, but can be use to collect other types of bodily fluids and/or biological tissues (e.g., epithelial cells, bone marrow, spinal fluid and the like) including, without limitation, abnormal tissue samples such as leukemias, cancer tissue cancer, and the like as long as the tissue samples-can be transformed into a cellular suspension.
  • bodily fluids and/or biological tissues e.g., epithelial cells, bone marrow, spinal fluid and the like
  • abnormal tissue samples such as leukemias, cancer tissue cancer, and the like as long as the tissue samples-can be transformed into a cellular suspension.
  • the device 100 includes an evacuated collection container 10 comprised of (1) a tube 12 having an open end 14 and a closed end 16; a closure (e.g., stopper) 18 in the open end of the tube 12, and a predetermined level of vacuum (not shown) inside the container 10.
  • the tube 12 is made of a transparent material such as glass or plastic for better visibility.
  • the tube 12 has an interior surface that is sterile and resists adherence to the cells 20 (not shown) during collection, storage, and analysis.
  • the closure 18 is preferably puncturable by a needle and resealable allowing easy transfer of the cells 20 (e.g., the cells 20 from its host to the container 10 and from the container 10 to another substrate if desired).
  • the closure 18 and the tube 12 together form a seal capable of maintaining a pressure differential between atmospheric pressure and a pressure less than atmospheric pressure within the tube 12.
  • the size of the container 10 is not narrowly critical and is dependent upon the cell sample volume that is desired to be collected and preserved.
  • a typical size for the container 10 may have an internal volume of between 100 ⁇ l to 10 ml.
  • the container 10 can be constructed using art-disclosed methods and is commercially available (e.g., Vacutainer Plus Plastic Tubes with Hemogard Closure available from Becton Dickinson and Company located in Franklin Lakes, New Jersey; the evacuated sample collection tube described in U.S. Patent No. 5,860,937 , which is incorporated by reference).
  • Vacutainer Plus Plastic Tubes with Hemogard Closure available from Becton Dickinson and Company located in Franklin Lakes, New Jersey
  • the evacuated sample collection tube described in U.S. Patent No. 5,860,937 , which is incorporated by reference.
  • the device 100 further includes compounds 22 including an anticoagulant agent 24, a fixative agent 26 selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5-dimethylhydantoin, dimethylol urea, 2-bromo-2-nitropropane-1,3-diol, oxaizolidines, sodium hydroxymethyl glycinate, 5-hydroxymethoxymethyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, 5-hydroxymethyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, 5-hydroxypoly[methyleneoxy]methyl-1-laza-3,7-dioxabicyclo[3.3.0]octane, and quaternary adamantine, and optionally a polyacrylic acid 28 or
  • a suitable amount of any art-disclosed anticoagulant agent such as ethylene diamine tetra acetic acid (EDT A) and its salts, ethylene glycol tetra acetic acid (EGTA) and its salts, hirudin, heparin, citric acid, salts of citric acid, oxalic acid, salts of oxalic acid, or mixtures thereof may be used.
  • EDT A ethylene diamine tetra acetic acid
  • EGTA ethylene glycol tetra acetic acid
  • hirudin heparin
  • citric acid salts of citric acid, oxalic acid, salts of oxalic acid, or mixtures thereof
  • a preferred anticoagulant agent 24 is K 3 EDTA.
  • the suitable amount of the anticoagulant agent 24 for the claimed subject matter is that effective to prevent coagulation of the cells 20 (e.g., whole blood) without causing significant dilution of the cells 20 (i.e., not clinically significant), and thereby allowing the cells 20, stored with the compounds 22, to be directly analyzed by a flow cytometer).
  • K 3 EDTA is the anticoagulant agent 24 and its concentration weight/volume is preferably less than about 0.3 g/ml, more preferably less than about 0.2 g/ml, and most preferably about less than about 0.15 g/ml.
  • the preferred fixative agent 26 is a heterocyclic urea (e.g., diazolidinyl urea (known as DU), imidazolidinyl urea (known as IDU) or a mixture thereof).
  • the most preferred fixative agent is diazolidinyl urea.
  • the suitable amount of the fixative agent 26 for-the claimed subject matter is that effective to fix or stabilize the cells 20 without causing significant dilution of the cells 20 (i.e., not clinically significant), and thereby allowing the cells 20, stored with the compounds 22, to be directly analyzed by a flow cytometer.
  • diazolidinyl urea is the fixative agent 26 and its concentration weight/volume is preferably about less than about 1 g/ml, more preferably less than about 0.75 g/ml, and most preferably less than about 0.5 g/ml. (concentration of solution of DU before blood sample is added.)
  • the acid 28 may rise signal to noise ratio during flow cytometry; and therefore, the acid 28 may be optionally added as one of the compounds 22 in the device 100.
  • the preferred acid 28 is a polycarboxylic acid, and more preferably a polyacrylic acid with a molecular weight of 5,000.
  • the suitable amount of the acid 28 for the claimed subject matter is that effective to rise signal to noise ratio during flow cytometry but without causing significant dilution to the cells 20 (i.e., not clinically significant) so that the cells 20, stored with the compounds 22, can be directly analyzed by a flow cytometry.
  • polyacrylic acid with a molecular weight of 5,000 is included in the container 10.
  • Additional compounds may optionally be added as one of the compounds 22 in the device 100.
  • Such additional and optional compounds may include: cell permeabilizing agents for substantially gaining access to intracellular analytes/epitopes and7or for lysing red blood cells; proteins that substantially protect the cells during processing and/or substantially reduce non-specific binding of probes; serum/lipoproteins that substantially protect cells during processing and/or substantially reduce non-specific binding of probes; RNAse inhibitors which substantially inhibit digestion of RNA and/or substantially maintain RNA integrity; nucleic acid stabilizers which substantially inhibit the degradation of nucleic acids and nucleic acid containing compounds; amino acids / polypeptides which substantially enhance binding of probes/antibodies to epitopes and/or substantially increases the observable signal; fixatives which substantially preserve cell integrity especially for permeabilization agents, and may preserve some epitopes; anticoagulants which substantially decreases clotting of red blood cells, chelates calcium and / or may help maintain WBC integrity/viability; protease inhibitor
  • additional and optional compounds may be more specifically include: Cell permeabilizing agents such as: DMSO (Dimethyl Sulfoxide), Ethylene glycol, Polyethylene glycol, Glycerin, Cellosolves (ethylene glycol dimethyl ether) (phenoxyethanol), Triton X 100, Triton X 705 (non-ionic detergents), 1-methyl-2-pyrrolidinone, Tween 20, Tween 40 (non-ionic), Brij 35 (detergent), Polyoxyethylene ether (Polyox), Sodium cholate, Ethylene oxide polymers, Monensin, Monactin, Pentachlorophenol, 2,4 dinitrophenol, saponin, SDS (sodium dodecyl sulfate); Proteins such as: Biotin, Albumins (egg, bovine), Gelatin, and similar such compounds as should
  • the claimed subject matter allows the final composition 30 to be transported in ambient temperature. Thereafter, it is preferred that the final composition 30 be stored at temperature less than about 40°C.
  • the cells 20 stored in the final composition 30 have more than about 3 days, preferably more than about 5 days, more preferably more than about 7 days stability.
  • the claimed subject matter allows the cells 20 stored in the final composition 30 to be directly analyzed by a flow cytometer without further dilution and/or treatment because the compounds 22 can preserve the cells 20 without significantly diluting the cells 20. Any significant dilution of the cells 20 is likely to cause error in flow cytometry measurements (e.g., lowering the lymphocytes' count).
  • the compounds 22 are in concentrated forms, preferably in a ratio with the final composition 30 that is less than about 2:100, more preferably less than about 1.5:100, and most preferably less than about 1:100.
  • the device 100 may be included in a kit of the claimed subject matter containing components 32 (not shown) conventionally used to collect and analyze the cells 20 such as alcohol swab, gauze, tube holder, tourniquet, glove, other cell collection tube (with or without conventional cell analysis additives inside such tube), needle (with hub, part of a syringe assembly including barrel and plunger, or with wings connected via a hub and tubing to another needle for delivery to the device 100 or other collection tubes), lancet, adhesive strip, syringe, test strip (allowing the cells 20 to flow directly onto a glass or plastic strip containing reagents for cell analysis), glass or plastic strip containing reagents for cell analysis (e.g., immunoassay), packaging means (e.g., plastic bag, compartmentalized plastic enclosure, and the like) to store the desired components 32 and the device 100, and packaging means to transport the cells 20 stored in the device 100 after collection. It is preferred that the packaging means and any other components 32 that may become in physical contact with the cells 20 be steriliz
  • the fixative agent 26 of the claimed subject matter has extremely low toxicity.
  • toxicity studies comparing diazolidinyl urea with formaldehyde of the prior art show the following: INHALATION TOXICITY DERMAL TOXICITY LD50 Formaldehyde 500 mg/kg 270 mg/kg 800 mg/kg Diazolidinyl Urea None 2000 mg/kg 2570 mg/kg
  • fixative agent 26 Another advantage offered by the fixative agent 26 is the fact that it is not flammable and therefore does not present a fire hazard as do many of the prior art fixative agents.
  • fixative agent 26 provides the desired tissue and cell membrane stabilization. It is believed that the fixative agent binds in some fashion to the cell membrane or tissue. This hypothesis is drawn because many members of the active agent are known disinfectants, which kill bacteria by binding to cell structure. This is not a full explanation of the mechanism responsible for the results of the claimed subject matter since many other disinfectants such as KATHON and OMADINE fail to provide tissue and cell stabilizing effects.
  • fixative agent 26 to preserve antigenic sites is also not understood but it is probably due to a difference in the reaction between proteins and the fixative agent 26 compared to prior art preservatives such as formaldehyde-Formaldehyde cross-links with itself and proteins to obscure the antigen.
  • diazolidinyl urea was added to the protein, albumin. After incubation of the diazolidinyl urea and protein mixture for 24 hours, disc-gel electrophoresis indicated no change in the rate of migration of the protein. When this experiment is conducted with formaldehyde, a large number of insoluble proteins result and the electrophoretic migration is altered.
  • a method of making the device 100 of the claimed subject matter is comprised of providing the tube 12 having the open end 14 and the closed end 16 (202). It is preferred that the tube 12 is sterile.
  • the method is further comprised of preloading (i.e., introducing) the compounds 22 comprising of the anticoagulant agent 24, the fixative agent 26, and optionally the acid 28 into the tube 12 using art-disclosed methods (204).
  • the types and amounts of the anticoagulant agent 24, the fixative agent 26, and optionally, the acid 28 including the ratio between the compounds 22 and the final composition 30 are the same as described above for the device 100 of the claimed subject matter. It is preferred the compounds have been sterilized (e.g., by sterile filtration).
  • the method of the preloading step 204 may optionally include freeze drying the compounds in the tube 12.
  • the method 200 further includes inserting the closure 18 into the open end 14 of the tube 12 (206).
  • the method 200 further includes drawing a vacuum inside the tube 12 to a predetermined level (208) using art-disclosed methods.
  • the amount of vacuum to be drawn is dependent upon the nature and volume of the cells desired to be collected and preserved. For example, for whole blood collection, the vacuum should be drawn to a level that allows the pressure of the whole blood to cause it to flow into and fill the tube 12 to the desired level.
  • the method 200 may optionally include providing the components 32 conventionally used to collect and analyze the cells 20.
  • the components 32 are the same as for the device 100 of the claimed subject matter as described above.
  • the method may also optionally include collecting the cells 20 using art-disclosed methods (e.g., venipuncture, use of a lancet, etc.). It may optionally include screening the cells 20 using art-disclosed instruments such as flow cytometers (eg., FACScan, FACSCalibur by BD and EPICS by Beckman Coulter), other hematology instruments (e.g., H3 by Bayer Corporation, the Beckman Coulter STKS or Gen-S Systems, the Abbott Cell-Dyn 4000 Hematology System, Bayer ADVIA 120 System, the Sysmex XE2100 System, and the like.
  • art-disclosed instruments such as flow cytometers (eg., FACScan, FACSCalibur by BD and EPICS by Beckman Coulter), other hematology instruments (e.g., H3 by Bayer Corporation, the Beckman Coulter STKS or Gen-S Systems, the Abbott Cell-Dyn 4000 Hematology System, Bayer AD
  • the screening of the cells may be for any purpose including, without limitation, for HIV, HPV, hepatitis, leukemia, cancer, and the like; other art-disclosed screening such as immunoassay, AIDS panel, and the like; and screening by methods disclosed in commonly owned United States Patent No. 4,788,139 (Ryan ) titled "Platelet aggregation reagent, reagent container and method of determining platelet aggregation in EDTA-anticoagulated blood", which is hereby incorporated by reference.
  • Cells 20 collected and preserved using the claimed subject matter may undergo histological study in any known conventional manner, such as through the use of paraffin sectioning equipment, staining, mounting on slides, or other common steps utilized prior to microscopic or other examination. The claimed subject matter thus provides a safe, convenient, and effective solution to collect and preserve cells for analysis.
  • the claimed subject matter may be used by those skilled in the art to preserve antigenic sites on or within cells (or components thereof) derived from any source including normal blood, bone marrow, lymph, or solid tissues, or may be derived from abnormal tissues such as leukemias or solid tissue cancers.
  • the claimed subject matter may also be utilized with any cellular component or biological material that has at least one antigenic site.
  • cell clumping is prevented, light scattering properties are preserved, antigenic sites are preserved, and nucleic acids may be analyzed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (14)

  1. Verwendung zum Stabilisieren innerhalb eines Röhrchens einer Probe von Vollblut, Ephitel- oder Rückenmarksflüssigkeitszellen, die in das Röhrchen eingesaugt wurden, zur anschließenden Analyse von nicht mehr als zwei Teilen einer Mischung aus einem Antikoagulanz und einem Fixiermittel pro hundert Teilen von der Probe, Antikoagulanz und Fixiermittel, wobei das Fixiermittel (26) ausgewählt wird aus der Gruppe bestehend aus Diazolidinylharnstoff und Imidazolidinylharnstoff und das Antikoagulanz Ethylendiamintetraessigsäure oder Salze davon umfasst.
  2. Verwendung gemäß Anspruch 1, wobei die Menge des Antikoagulanz so bemessen ist, dass es weniger als etwa 0,3 g/ml bereitstellt.
  3. Verwendung gemäß Anspruch 1 oder Anspruch 2, wobei die Menge des Fixiermittels so bemessen ist, dass es weniger als etwa 1 g/ml bereitstellt.
  4. Verwendung gemäß einem der Ansprüche 1 bis 3, wobei die Mischung eine Polyacrylsäure enthält.
  5. Verfahren zum Präparieren von Vollblut, Ephitel- oder Rückenmarksflüssigkeitszellen für Analysen umfassend das Einsaugen einer Zellenprobe unter Vakuum in ein Röhrchen, wobei das Röhrchen eine stabilisierende Mischung enthält, umfassend eine Mixtur aus einem Fixiermittel und einem Antikoagulanz, wobei das Fixiermittel ausgewählt ist aus Diazolidinylharnstoff und Imidazolidinylharnstoff und das Antikoagulanz ausgewählt ist aus Ethylendiamintetraessigsäure und Salzen davon, wobei die Menge der stabilisierenden Mischung in dem Röhrchen weniger als zwei Teile pro hundert Teile von der Probe, des Antikoagulanz und des Fixiermittels vorsieht, wenn die Probe in das Röhrchen eingesaugt wird.
  6. Verfahren gemäß Anspruch 5, wobei die stabilisierende Mischung Glycin beinhaltet.
  7. Verfahren gemäß Anspruch 5 oder Anspruch 6, wobei die Zellen zur Analyse bei Umgebungstemperatur transportiert werden.
  8. Verfahren gemäß einem der Ansprüche 5 bis 7, beinhaltend das Transportieren der Zellprobe bei Umgebungstemperatur zur direkten Analyse mittels Durchflusszytometrie ohne weitere Verdünnung oder Behandlung.
  9. Das Verfahren gemäß einem der Ansprüche 5 bis 8, wobei die Konzentration von Diazolidinylharnstoff geringer als 1 g/ml ist.
  10. Verfahren gemäß einem der Ansprüche 5 bis 9, wobei das Antikoagulanz K3EDTA ist und die Konzentration dieses Antikoagulanz geringer als 0,3 g/ml ist.
  11. Verfahren gemäß einem der Ansprüche 5 bis 10, wobei das Verfahren das Screening der Zellprobe zur Analyse auf Festgewebekarzinome beinhaltet.
  12. Verfahren gemäß einem der Ansprüche 5 bis 11, wobei die stabilisierende Mischung in dem Röhrchen weniger als ein Teil pro hundert Teile von der Probe, des Antikoagulanz und des Fixiermittels bereitstellt.
  13. Verfahren gemäß einem der Ansprüche 5 bis 12, beinhaltend das Entnehmen der Zellprobe durch Venenpunktion.
  14. Verfahren gemäß einem der Ansprüche 5 bis 13, wobei das Röhrchen aus transparentem Plastik ist.
EP07008752.3A 2002-10-16 2003-10-16 Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse Expired - Lifetime EP1816461B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41897802P 2002-10-16 2002-10-16
EP20030256535 EP1413874A1 (de) 2002-10-16 2003-10-16 Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP20030256535 Division EP1413874A1 (de) 2002-10-16 2003-10-16 Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse

Publications (2)

Publication Number Publication Date
EP1816461A1 EP1816461A1 (de) 2007-08-08
EP1816461B1 true EP1816461B1 (de) 2020-01-08

Family

ID=38226808

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07008752.3A Expired - Lifetime EP1816461B1 (de) 2002-10-16 2003-10-16 Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse

Country Status (1)

Country Link
EP (1) EP1816461B1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
ES2649572T3 (es) 2009-02-18 2018-01-12 Streck Inc. Conservación de ácidos nucleicos fuera de las células
EP2704740B1 (de) 2011-05-04 2016-10-05 Streck, Inc. Inaktiviertes schweinegrippe-virus und verfahren zu seiner herstellung
EP2793569B1 (de) 2011-12-22 2019-04-03 Absolute Liquid Solutions ApS Ausgabeeinheit
CA2917912C (en) 2013-07-24 2019-09-17 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
EP3491381B1 (de) 2016-07-29 2025-09-24 Streck LLC Suspensionszusammensetzung zur kontrolle einer hämatologischen analyse
EP3571314B1 (de) 2017-01-22 2023-12-20 Chryos, LLC Zusammensetzung und verfahren zur verwendung davon zur konservierung von zellen zur analyse
EP3576625A4 (de) * 2017-02-03 2020-12-16 Streck, Inc. Probensammelröhrchen mit konservierungsmittel
HUE068517T2 (hu) 2017-10-19 2024-12-28 Streck Llc A hemolízis és a véralvadás szabályozására, valamint az extracelluláris vezikulák stabilizálására szolgáló készítmények
CN109090104A (zh) * 2018-09-27 2018-12-28 广州新诚生物科技有限公司 保存液及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618664A (en) * 1992-11-03 1997-04-08 Kiessling; Ann A. Process for simultaneously disinfecting and fixing biological fluids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675159A (en) * 1985-09-29 1987-06-23 Al Sioufi Habib Method and device for disinfecting biological fluids and container for same
US4788139A (en) 1987-08-06 1988-11-29 Streck Laboratories, Inc. Platelet aggregation reagent, reagent container and method of determining platelet aggregation in EDTA-anticoagulated blood
US5849517A (en) * 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
US5260048A (en) * 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5998483A (en) * 1991-09-20 1999-12-07 Camiener; Gerald W. Glyoxal-containing preservative compositions
US5860937A (en) 1997-04-30 1999-01-19 Becton, Dickinson & Company Evacuated sample collection tube with aqueous additive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618664A (en) * 1992-11-03 1997-04-08 Kiessling; Ann A. Process for simultaneously disinfecting and fixing biological fluids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis

Also Published As

Publication number Publication date
EP1816461A1 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
US20210267191A1 (en) Method and device for collecting and preserving cells for analysis
US9029076B2 (en) Tissue preservation and fixation method
EP1816461B1 (de) Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse
US10774359B2 (en) Cellular analysis of body fluids
AU2007203372B2 (en) Universal collection medium
US20100099074A1 (en) Collection device and method for stimulating and stabilizing a biological sample
WO1998002740A1 (en) Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
JP2019090814A (ja) サンプル分析のための方法、機器、及びシステム
EP1217372A1 (de) Verbessertes Durchflusszytometriereagenz und System
JP3523883B2 (ja) 血液検査の実施方法
Tammen Specimen collection and handling: standardization of blood sample collection
JP3759512B2 (ja) 脳脊髄液などの体液試料をアッセイするための自動法およびそのための試薬
US7745219B2 (en) Reagent composition for the analysis of residual white blood cells in leuko-reduced blood banking products
JP2020030180A (ja) 血液試料の溶血剤
JP6871729B2 (ja) マラリア原虫に感染した赤血球の検出方法及び血液分析装置
McCoy Jr Preparation of cells from blood
EP3571314B1 (de) Zusammensetzung und verfahren zur verwendung davon zur konservierung von zellen zur analyse
JP2025514006A (ja) 生物学的試料を分析するためのキュベット
JP2025509758A (ja) キュベットをコーティングするための組成物及びキュベットをコーティングするための組成物の製造方法
KR20240159970A (ko) 큐벳 내의 생물학적 샘플의 이미지를 얻는 방법
Freemont et al. Techniques for the Examination of Synovial Fluid—General Remarks
HK40048617A (en) Microsampling detection in diabetes
Ormerod Flow cytometric analysis of cells using an antibody to a surface antigen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070430

AC Divisional application: reference to earlier application

Ref document number: 1413874

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20080408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190524

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20191030

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60352358

Country of ref document: DE

Owner name: STRECK INC., LA VISTA, US

Free format text: FORMER OWNER: STRECK LABORATORIES, INC., LA VISTA, NEV., US

AC Divisional application: reference to earlier application

Ref document number: 1413874

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60352358

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1223294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200215

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200408

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER AND CIE S.A., CH

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: STRECK INC., US

Free format text: FORMER OWNER: STRECK LABORATORIES, INC., US

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: STRECK, INC.

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 34101

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60352358

Country of ref document: DE

Representative=s name: SCHUMACHER & WILLSAU PATENTANWALTSGESELLSCHAFT, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 60352358

Country of ref document: DE

Owner name: STRECK INC., LA VISTA, US

Free format text: FORMER OWNER: STRECK LABORATORIES, INC., LA VISTA, NEV., US

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200531

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: STRECK, INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: STRECK LABORATORIES, INC.

Effective date: 20200616

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: STRECK, INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE; FORMER OWNER NAME: STRECK LABORATORIES, INC.

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200409

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2784011

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200921

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60352358

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

REG Reference to a national code

Ref country code: AT

Ref legal event code: HC

Ref document number: 1223294

Country of ref document: AT

Kind code of ref document: T

Owner name: STRECK, INC., US

Effective date: 20210122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200108

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20220914

Year of fee payment: 20

Ref country code: NL

Payment date: 20220916

Year of fee payment: 20

Ref country code: GB

Payment date: 20220908

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220908

Year of fee payment: 20

Ref country code: BE

Payment date: 20220916

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220913

Year of fee payment: 20

Ref country code: ES

Payment date: 20221104

Year of fee payment: 20

Ref country code: DK

Payment date: 20221011

Year of fee payment: 20

Ref country code: DE

Payment date: 20220914

Year of fee payment: 20

Ref country code: AT

Payment date: 20220926

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221010

Year of fee payment: 20

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1223294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200108

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60352358

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20231015

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20231016

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 34101

Country of ref document: SK

Expiry date: 20231016

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20231015

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20231016

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231204

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 1223294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231016

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231015

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20231017